Tang Li, Cheng Hongfa, Yang Qiuyue, Xie Yahui, Zhang Qiuxia
College of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Front Pharmacol. 2025 Mar 17;16:1552579. doi: 10.3389/fphar.2025.1552579. eCollection 2025.
Rhodiola is a common Chinese herb in the treatment of cerebral small vessel disease (cSVD). Umbelliferone, one of the effective components of Rhodiola, can protect the endothelial barrier. But its mechanisms are still unclear. Therefore, this study is aimed to explore mechanisms of umbelliferone of an effective component of Rhodiola in protecting the cerebral microvascular endothelial barrier in cSVD.
Firstly, ETCM, SwissTargetPrediction and literatures were used to screen components and targets of Rhodiola. GeneCards was used to obtain targets of cSVD. STRING and Cytoscape were utilized for building the PPI and C-T network. Metascape was utilized to construct GO and KEGG enrichment analysis. Then, molecular docking was employed to evaluate the binding ability of the compounds for their respective target molecules. Ultimately, the endothelial cell damage caused by OGD was employed to explore the protective impact of umbelliferone, a bioactive constituent of Rhodiola, on the endothelial barrier. Endothelial cell leakage and migration assays were used to assess the permeability and migration ability of endothelial cells. IF and WB techniques were employed to ascertain the expression of endothelial tight junction protein. The major target proteins and related pathways were validated by WB.
Six effective components and 106 potential targets were identified and 1885 targets of cSVD were obtained. Nine key targets were selected. GO and KEGG enrichment analysis suggested that effects of Rhodiola in cSVD were associated with PI3K-Akt, Ras, Rap1 and MAPK signal pathways. Molecular docking results showed good binding ability between 28 pairs of key proteins and compounds. Umbelliferone of an effective component of Rhodiola can protect tight junction proteins and improve the permeability and migration ability of endothelial cells damaged by OGD through MMP9, MMP2, CCND1, PTGS2 and PI3K-Akt, Ras, Rap1 signaling pathways.
Our study systematically clarified mechanisms of Rhodiola in treating cSVD by network pharmacology and molecular docking, characterized by its multi-component, multi-target and multi-pathway effects. This finding was validated through tests, which demonstrated that umbelliferone of an effective component in Rhodiola can protect the brain microvascular endothelial barrier. It provided valuable ideas and references for additional research.
红景天是治疗脑小血管病(cSVD)常用的一味中药。伞形花内酯是红景天的有效成分之一,可保护内皮屏障。但其作用机制尚不清楚。因此,本研究旨在探讨红景天有效成分伞形花内酯保护cSVD脑微血管内皮屏障的机制。
首先,利用中药系统药理学数据库(ETCM)、瑞士靶点预测工具(SwissTargetPrediction)及文献筛选红景天的成分和靶点。利用基因卡片(GeneCards)获取cSVD的靶点。利用STRING和Cytoscape构建蛋白质-蛋白质相互作用(PPI)网络和成分-靶点(C-T)网络。利用Metascape进行基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析。然后,采用分子对接评估化合物与各自靶分子的结合能力。最后,采用氧糖剥夺(OGD)诱导的内皮细胞损伤,探讨红景天生物活性成分伞形花内酯对内皮屏障的保护作用。采用内皮细胞渗漏和迁移实验评估内皮细胞的通透性和迁移能力。采用免疫荧光(IF)和蛋白质免疫印迹(WB)技术确定内皮紧密连接蛋白的表达。通过WB验证主要靶蛋白和相关信号通路。
共鉴定出6种有效成分和106个潜在靶点,获得1885个cSVD靶点。筛选出9个关键靶点。GO和KEGG富集分析表明,红景天在cSVD中的作用与磷脂酰肌醇-3激酶-蛋白激酶B(PI3K-Akt)、Ras、Rap1和丝裂原活化蛋白激酶(MAPK)信号通路相关。分子对接结果显示28对关键蛋白与化合物之间具有良好的结合能力。红景天有效成分伞形花内酯可通过基质金属蛋白酶9(MMP9)、基质金属蛋白酶2(MMP2)、细胞周期蛋白D1(CCND1)、前列腺素内过氧化物合酶2(PTGS2)以及PI3K-Akt、Ras、Rap1信号通路保护紧密连接蛋白,提高OGD损伤内皮细胞的通透性和迁移能力。
本研究通过网络药理学和分子对接系统阐明了红景天治疗cSVD的机制,其具有多成分、多靶点、多通路的特点。通过实验验证了该发现,结果表明红景天有效成分伞形花内酯可保护脑微血管内皮屏障。本研究为进一步研究提供了有价值的思路和参考。